UNLABELLED: Following treatment of hepatitis B virus (HBV) infection with nucleos(t)ide reverse transcriptase inhibitors (NRTIs), there is a biphasic clearance of HBV, similar to that seen following treatment of human immunodeficiency virus-1 (HIV-1) and hepatitis C virus. Little is known about the impact of combination NRTIs and HIV-1 coinfection on HBV viral kinetic parameters following the initiation of HBV-active highly active antiretroviral therapy (HAART). HIV-1-HBV coinfected patients (n = 21) were enrolled in a viral kinetics substudy of the Tenofovir in HIV-1-HBV Coinfection study (TICO). TICO was a randomized (1:1:1) trial of tenofovir disoproxil fumarate (TDF, 300 mg) versus lamivudine (LMV, 300 mg) versus TDF/LMV within an efavirenz based HAART regimen initiated in HIV-1-HBV coinfected antiretroviral naïve individuals in Thailand. HBV DNA was measured frequently over the first 56 days. To fit the viral load data, we used a model of HBV kinetics that allows the estimation of treatment effectiveness, viral clearance and infected cell loss. We observed a biphasic decline in HBV DNA in almost all patients. We did not observe any significant differences in HBV viral dynamic parameters between the three treatments groups. Overall, median (interquartile range) HBV treatment effectiveness was 98% (95%-99%), median HBV virion half-life was 1.2 days (0.5-1.4 days), and median infected cell half-life was 7.9 days (6.3-11.0 days). When we compared hepatitis B e antigen (HBeAg)-positive and HBeAg-negative individuals, we found a significantly longer infected cell half-life in HBeAg-positive individuals (6.2 versus 9.0 days, P = 0.02). CONCLUSION:HBV viral dynamic parameters are similar following anti-HBV NRTI monotherapy and dual combination therapy in the setting of HIV-1-HBV coinfection. HIV-1 coinfection has minimal effect on HBV viral dynamics, even in the setting of advanced HIV-1-related immunosuppression.
RCT Entities:
UNLABELLED: Following treatment of hepatitis B virus (HBV) infection with nucleos(t)ide reverse transcriptase inhibitors (NRTIs), there is a biphasic clearance of HBV, similar to that seen following treatment of human immunodeficiency virus-1 (HIV-1) and hepatitis C virus. Little is known about the impact of combination NRTIs and HIV-1 coinfection on HBV viral kinetic parameters following the initiation of HBV-active highly active antiretroviral therapy (HAART). HIV-1-HBV coinfectedpatients (n = 21) were enrolled in a viral kinetics substudy of the Tenofovir in HIV-1-HBV Coinfection study (TICO). TICO was a randomized (1:1:1) trial of tenofovir disoproxil fumarate (TDF, 300 mg) versus lamivudine (LMV, 300 mg) versus TDF/LMV within an efavirenz based HAART regimen initiated in HIV-1-HBV coinfected antiretroviral naïve individuals in Thailand. HBV DNA was measured frequently over the first 56 days. To fit the viral load data, we used a model of HBV kinetics that allows the estimation of treatment effectiveness, viral clearance and infected cell loss. We observed a biphasic decline in HBV DNA in almost all patients. We did not observe any significant differences in HBV viral dynamic parameters between the three treatments groups. Overall, median (interquartile range) HBV treatment effectiveness was 98% (95%-99%), median HBV virion half-life was 1.2 days (0.5-1.4 days), and median infected cell half-life was 7.9 days (6.3-11.0 days). When we compared hepatitis B e antigen (HBeAg)-positive and HBeAg-negative individuals, we found a significantly longer infected cell half-life in HBeAg-positive individuals (6.2 versus 9.0 days, P = 0.02). CONCLUSION:HBV viral dynamic parameters are similar following anti-HBV NRTI monotherapy and dual combination therapy in the setting of HIV-1-HBV coinfection. HIV-1 coinfection has minimal effect on HBV viral dynamics, even in the setting of advanced HIV-1-related immunosuppression.
Authors: Y Benhamou; M Bochet; V Thibault; V Di Martino; E Caumes; F Bricaire; P Opolon; C Katlama; T Poynard Journal: Hepatology Date: 1999-11 Impact factor: 17.425
Authors: R A de Man; L M Wolters; F Nevens; D Chua; M Sherman; C L Lai; A Gadano; Y Lee; F Mazzotta; N Thomas; D DeHertogh Journal: Hepatology Date: 2001-09 Impact factor: 17.425
Authors: J Audsley; N Arrifin; L K W Yuen; A Ayres; S M Crowe; A Bartholomeusz; S A Locarnini; A Mijch; S R Lewin; J Sasadeusz Journal: HIV Med Date: 2009-01-28 Impact factor: 3.180
Authors: Louise Cooley; Anna Ayres; Angeline Bartholomeusz; Sharon Lewin; Suzanne Crowe; Anne Mijch; Stephen Locarnini; Joseph Sasadeusz Journal: AIDS Date: 2003-07-25 Impact factor: 4.177
Authors: Gregory J Dore; David A Cooper; Anton L Pozniak; Edwin DeJesus; Lijie Zhong; Michael D Miller; Biao Lu; Andrew K Cheng Journal: J Infect Dis Date: 2004-03-12 Impact factor: 5.226
Authors: Jeremie Guedj; Yaron Rotman; Scott J Cotler; Christopher Koh; Peter Schmid; Jeff Albrecht; Vanessa Haynes-Williams; T Jake Liang; Jay H Hoofnagle; Theo Heller; Harel Dahari Journal: Hepatology Date: 2014-10-27 Impact factor: 17.425
Authors: K J Cortez; M A Proschan; L Barrett; D G Brust; Barry Weatherley; E Formentini; R T Davey; H Masur; M A Polis; A U Neumann And; S Kottilil Journal: HIV Clin Trials Date: 2013 Jul-Aug